Blueprint Medicines Corp (BPMC): Jeffrey W. Albers , CEO and President of Blueprint Medicines Corp sold 17,000 shares on Jun 3, 2016. The Insider selling transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were sold at $20.03 per share for a total value of $340,510.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 14, 2016, Christoph Lengauer (Chief Scientific Officer) sold 15,872 shares at $20.01 per share price.On Apr 8, 2016, Jeffrey W. Albers (CEO and President) sold 17,000 shares at $20.42 per share price.Also, On Nov 30, 2015, Llc Fmr (other) sold 287,415 shares at $21.57 per share price.
Blueprint Medicines Corp: On Friday, Jun 3, 2016 heightened volatility was witnessed in Blueprint Medicines Corp which led to swings in the share price. The shares opened for trading at $19.42 and hit $20.84 on the upside , eventually ending the session at $20.36, with a gain of 3.61% or 0.71 points. The heightened volatility saw the trading volume jump to 4,60,949 shares. The 52-week high of the share price is $37.17 and the company has a market cap of $555 M . The 52-week low of the share price is at $13.04.
Company has been under the radar of several Street Analysts.Blueprint Medicines Corp is Initiated by Raymond James to Outperform and the brokerage firm has set the Price Target at $23. The Rating was issued on May 27, 2016.
Blueprint Medicines Corporation (Blueprint) is a biopharmaceutical company. The Company is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. The Company developed a molecule drug pipeline in cancer and a genetic disease. Its lead drug candidate BLU-285 targets KIT Exon 17 and PDGFRa D842V active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. The Company’s BLU-285 is developed for patients with systemic mastocytosis (SM) and defined subsets of patients with gastrointestinal stromal tumor (GIST). The Company’s Imatinib which is an inhibitor of KIT and PDGFRa is approved in SM and GIST. The Company’s other drug candidate is BLU-554 which targets FGFR4 a kinase that is activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma. The Company is also developing a drug candidate to target both RET and RET resistant mutants.